Chongqing Zhifei Biological Products (300122) Fundamentals 2026 — Revenue Analysis | SniperIQ
Chongqing Zhifei Biological Products (300122) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥31.0B, trading at ¥12.95 on the SHZ. This SniperIQ fundamentals page covers Chongqing Zhifei Biological Products's valuation, profitability (net margin -169.5%), revenue (¥9.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Chongqing Zhifei Biological Products's market cap?
Chongqing Zhifei Biological Products (300122) has a market capitalization of approximately ¥31.0B, trading at ¥12.95 on the SHZ. Market cap moves with the live share price.
What is Chongqing Zhifei Biological Products's P/E ratio?
Chongqing Zhifei Biological Products's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Chongqing Zhifei Biological Products?
Chongqing Zhifei Biological Products runs a net profit margin of -169.5%, a gross margin of -150.3%, and an operating margin of -200.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Chongqing Zhifei Biological Products generate?
Chongqing Zhifei Biological Products reported revenue of ¥9.0B for fiscal year 2025, with net income of -¥14.7B and earnings per share (EPS) of -6.15. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Chongqing Zhifei Biological Products pay a dividend?
Chongqing Zhifei Biological Products does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Chongqing Zhifei Biological Products financially healthy?
Chongqing Zhifei Biological Products carries a debt-to-equity ratio of 0.73x and a current ratio of 3.14x, with a market beta of 1.29. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Chongqing Zhifei Biological Products a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Chongqing Zhifei Biological Products (300122) the key facts are: market cap ¥31.0B, revenue ¥9.0B, 52-week range 11.07-26. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Chongqing Zhifei Biological Products's full fundamentals live
Get Chongqing Zhifei Biological Products's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.